FDA OK for Pfizer's Xalkori and Companion Dx Highlights Upside for PGx Strategies in Drug Development
September 07, 2011
FDA OK for Pfizer's Xalkori and Companion Dx Highlights Upside for PGx Strategies in Drug Development
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Early Data Convinces Some Oncologists to Treat ROS1-Positive NSCLC Patients with Xalkori
June 6, 2012 / Pharmacogenomics Reporter - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - Pfizer's PGx NSCLC Drug Yields Promising PFS Results; More Research Needed to Map Disease Mechanism
June 8, 2011 / Pharmacogenomics Reporter - Pfizer and Collaborators Developing Next-Gen Sequencing Test for Crizotinib Resistance Mutations
March 27, 2013 / Pharmacogenomics Reporter - Abbott Challenges 'Incorrect Assumptions' in Cost-Effectiveness Study of Xalkori PGx Testing
March 28, 2012 / Pharmacogenomics Reporter